Neuromodulation Devices Market to Grow at a CAGR of ~8.95% by 2032, Fueled by Advancements in Neurological Therapies and Rising Prevalence of Neurological Disorders | DelveInsight
DelveInsight’s Neuromodulation Devices Market Insights report provides the current and forecast market analysis, individual leading neuromodulation device companies’ market shares, challenges, neuromodulation device market drivers, barriers, and trends, and key neuromodulation device companies in the market.
Key Takeaways from the Neuromodulation Devices Market Report
• The neuromodulation devices market was valued at USD 5.71 billion in 2023 and is projected to reach USD 9.56 billion by 2032, growing at a CAGR of 8.95% from 2025 to 2032.
• As per DelveInsight estimates, North America is anticipated to dominate the global neuromodulation devices market during the forecast period.
• Notable neuromodulation devices companies such as Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP, Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and several others are currently operating in the neuromodulation devices market.
• In March 2025, Sooma Medical announced it received FDA Investigational Device Exemption (IDE) for its transcranial direct current stimulation (tDCS) device. This approval allows the company to begin a pivotal study of the device. Based in Helsinki, Finland, Sooma designed the tDCS device to treat depression through portable neuromodulation.
• In Feb 2025, Medtronic received FDA approval for its BrainSense™ Adaptive deep brain stimulation (aDBS) for Parkinson’s disease, marking a significant advancement in neuromodulation therapy.
• In December 2024, ShiraTronics announced the initiation of its FDA investigational device exemption (IDE) pivotal trial for its neuromodulation therapy. The RELIEV-CM2 clinical study will evaluate the therapy for chronic migraine, with the first implants completed in the U.S. and Australia. The study aims to assess the long-term safety and efficacy of the system. In October, the company raised $66 million to support the trial’s launch.
• In September 2024, Turing Medical received FDA 510(k) clearance for its Bullsai Identify platform. This advanced, automated solution provides precise, personalized data to aid in planning neuromodulation therapies for neurological conditions like Parkinson’s disease and essential tremor.
• In January 2024, Boston Scientific Corporation announced that it had entered into a definitive agreement to acquire Axonics, Inc. for an amount of USD 3.4 billion. Through this acquisition, Boston Scientific expanded its neurostimulation device product portfolio with advanced technology development in sacral neuromodulation.
To read more about the latest highlights related to the neuromodulation devices market, get a snapshot of the key highlights entailed in the Global Neuromodulation Devices Market Report
Neuromodulation Devices Overview
Neuromodulation devices are medical technologies designed to alter nerve activity through targeted delivery of electrical, chemical, or magnetic signals. These devices are used to treat a range of neurological and chronic conditions, including chronic pain, depression, epilepsy, Parkinson’s disease, and migraines, among others. The core mechanism of neuromodulation involves stimulating or inhibiting specific nerve pathways to restore normal function or alleviate symptoms. These devices can be implanted or non-invasive, and they include systems such as deep brain stimulators, spinal cord stimulators, transcranial magnetic stimulators, and peripheral nerve stimulators. As the demand for non-pharmacological treatments grows and the global burden of neurological disorders increases, the neuromodulation devices market continues to expand, with ongoing research focused on enhancing device efficacy, precision, and patient outcomes.
Neuromodulation Devices Market Insights
North America is expected to lead the neuromodulation devices market during the forecast period, driven by the rising prevalence of neurological disorders and increasing product development by key industry players. The aging population in the region, with a growing number of individuals suffering from conditions such as Alzheimer’s disease and epilepsy, further fuels market growth. The ongoing efforts to develop advanced neuromodulation devices tailored for conditions like drug-resistant epilepsy are helping expand the market. Additionally, the Asia-Pacific region is poised for significant growth, supported by improving healthcare infrastructure, rising income levels, and a growing elderly population. Product development activities, such as the introduction of non-invasive neuromodulation devices for migraine and depression, will also contribute to the market’s expansion in the region.
To know more about why North America is leading the market growth in the neuromodulation devices market, get a snapshot of the Neuromodulation Devices Market Outlook
Neuromodulation Devices Market Dynamics
The rising prevalence of neurological disorders is expected to significantly drive the neuromodulation devices market, as these devices are increasingly applied in the treatment of various conditions. Migraine and other headache disorders affected a substantial portion of the global population in recent years, and neurological conditions like Parkinson’s disease are expected to see rising numbers, with a growing patient base fueling demand for effective treatments.
Moreover, the increasing cases of chronic pain, such as lower back pain, due to population growth and aging demographics, will further drive the need for neuromodulation devices designed to offer relief. The focus on innovation is also evident in the development of advanced neuromodulation systems, like the SAINT system for major depressive disorder, which uses MRI scans and algorithms to enhance treatment precision and outcomes. However, factors such as high device costs and potential complications may hinder market growth. Despite these challenges, the market is poised for expansion as demand for advanced treatment options continues to rise.
Get a sneak peek at the neuromodulation devices market dynamics @ https://www.delveinsight.com/report-store/neuromodulation-devices-market
Coverage: Global
Study Period: 2022 to 2032
Neuromodulation Devices Market CAGR: ~8.95%
Key Neuromodulation Devices Companies: Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP, Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others.
Neuromodulation Devices Market Segmentation
Market Segmentation By Type: Invasive and Non-Invasive.
Market Segmentation By Product: Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and others.
Market Segmentation By Application: Pain Management, Neurological Disorder, Respiratory Disorders, and others.
Market Segmentation By End User: Hospitals, Specialty Clinics, and others.
Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World.
Which MedTech key players in the neuromodulation devices market are set to emerge as the trendsetter, explore @ Neuromodulation Devices Companies
Table of Contents
1. Electrophysiology Devices Market Report Introduction
2. Electrophysiology Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Electrophysiology Devices Market Key Factors Analysis
6. Electrophysiology Devices Market Porter’s Five Forces Analysis
7. Electrophysiology Devices Market Layout
8. Electrophysiology Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
